Literature DB >> 24865638

Memory deficits correlate with tau and spine pathology in P301S MAPT transgenic mice.

Hong Xu1, Thomas W Rösler, Thomas Carlsson, Anderson de Andrade, Julius Bruch, Matthias Höllerhage, Wolfgang H Oertel, Günter U Höglinger.   

Abstract

AIM: P301SMAPT transgenic mice (P301S mice) are a widely used model of frontotemporal dementia and parkinsonism linked to chromosome 17 with tau pathology (FTDP-17-tau). However, a systematic correlation between cognitive deficits and cellular tau pathology at different ages is still missing. Therefore, our study investigated memory deficits of P301S mice in relation to pathological tau species and dendritic spine pathology throughout adulthood.
METHODS: We analysed P301S mice behaviourally with the novel open field, rotarod, and Morris water maze tests to measure deficits in locomotion, balance and cognition, respectively; immunohistochemically with different tau antibodies for specific tau species; and with Golgi staining for dendritic spine pathology.
RESULTS: We confirmed the occurrence of locomotor deficits at an age of 5 months and newly report memory deficits from 2.5 months of age onwards. At this early age, MC1 and CP13, but not AT180 immunoreactivity, was prominent in the hippocampus of P301S mice. Neuronal cell loss in the hippocampus of P301S mice was not observed to occur till 6 months of age. However, there was a significant reduction in the density of dendritic spines from young adulthood onwards in hippocampal pyramidal neurones.
CONCLUSION: In P301S mice, memory deficits precede the onset of locomotor dysfunction and coincide with the appearance of conformationally changed, S202-phosphorylated tau and reduced spine density in the absence of neuronal cell loss in the hippocampus. Our finding provides insights into the toxic effects of different tau species in vivo and may facilitate the development of new therapies against neurodegenerative tauopathies.
© 2014 British Neuropathological Society.

Entities:  

Keywords:  FTDP-17-tau; P301S transgenic mouse; dendritic spine; memory deficit; tau; tauopathy

Mesh:

Substances:

Year:  2014        PMID: 24865638     DOI: 10.1111/nan.12160

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  13 in total

1.  AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy.

Authors:  A Borreca; V Latina; V Corsetti; S Middei; S Piccinin; F Della Valle; R Bussani; M Ammassari-Teule; R Nisticò; P Calissano; G Amadoro
Journal:  Mol Neurobiol       Date:  2018-03-05       Impact factor: 5.590

2.  APPsα Rescues Tau-Induced Synaptic Pathology.

Authors:  Charlotte S Bold; Danny Baltissen; Susann Ludewig; Michaela K Back; Jennifer Just; Lara Kilian; Susanne Erdinger; Marija Banicevic; Lena Rehra; Fadi Almouhanna; Martina Nigri; David P Wolfer; Roman Spilger; Karl Rohr; Oliver Kann; Christian J Buchholz; Jakob von Engelhardt; Martin Korte; Ulrike C Müller
Journal:  J Neurosci       Date:  2022-06-06       Impact factor: 6.709

3.  Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies.

Authors:  Benjamin Chun-Kit Tong; Alexis Shiying Huang; Aston Jiaxi Wu; Ashok Iyaswamy; Olivia Ka-Yi Ho; Anna Hau-Yee Kong; Sravan Gopalkrishnashetty Sreenivasmurthy; Zhou Zhu; Chengfu Su; Jia Liu; Juxian Song; Min Li; King-Ho Cheung
Journal:  J Biomed Sci       Date:  2022-10-22       Impact factor: 12.771

4.  Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.

Authors:  David J Koss; Glynn Jones; Anna Cranston; Heidi Gardner; Nicholas M Kanaan; Bettina Platt
Journal:  Acta Neuropathol       Date:  2016-10-21       Impact factor: 17.088

5.  α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice.

Authors:  Yan-Hui Zhang; Da-Wei Wang; Shuang-Feng Xu; Shuai Zhang; Yong-Gang Fan; Ying-Ying Yang; Shi-Qi Guo; Shan Wang; Tian Guo; Zhan-You Wang; Chuang Guo
Journal:  Redox Biol       Date:  2017-11-07       Impact factor: 11.799

6.  PERK activation mitigates tau pathology in vitro and in vivo.

Authors:  Julius Bruch; Hong Xu; Thomas W Rösler; Anderson De Andrade; Peer-Hendrik Kuhn; Stefan F Lichtenthaler; Thomas Arzberger; Konstanze F Winklhofer; Ulrich Müller; Günter U Höglinger
Journal:  EMBO Mol Med       Date:  2017-03       Impact factor: 12.137

7.  Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning.

Authors:  Florian Eckenweber; Jose Medina-Luque; Tanja Blume; Christian Sacher; Gloria Biechele; Karin Wind; Maximilian Deussing; Nils Briel; Simon Lindner; Guido Boening; Barbara von Ungern-Sternberg; Marcus Unterrainer; Nathalie L Albert; Andreas Zwergal; Johannes Levin; Peter Bartenstein; Paul Cumming; Axel Rominger; Günter U Höglinger; Jochen Herms; Matthias Brendel
Journal:  J Neuroinflammation       Date:  2020-07-13       Impact factor: 8.322

8.  Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease.

Authors:  Jacki M Rorabaugh; Termpanit Chalermpalanupap; Christian A Botz-Zapp; Vanessa M Fu; Natalie A Lembeck; Robert M Cohen; David Weinshenker
Journal:  Brain       Date:  2017-11-01       Impact factor: 15.255

Review 9.  Dendritic Spines: Mediators of Cognitive Resilience in Aging and Alzheimer's Disease.

Authors:  Courtney K Walker; Jeremy H Herskowitz
Journal:  Neuroscientist       Date:  2020-08-19       Impact factor: 7.235

10.  TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits.

Authors:  Hongjie Wang; Ruizhi Wang; Ivan Carrera; Shaohua Xu; Madepalli K Lakshmana
Journal:  eNeuro       Date:  2016-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.